Dr Alexander van Akkooi speaks to ecancer at the 2019 EORTC Groups Annual Meeting (EGAM) about the latest research updates from the EORTC melanoma group.
Dr van Akkooi mentions a novel study that will examine the effects of BRAF- and MEK-directed therapy in combination with immunotherapy compared to immunotherapy alone. Additionally, this developing study will be aimed at BRAF-mutated, stage III, high-risk patients, or stage IV resected patients.
He also states a decline in the approval of melanoma drugs, along with inconsistencies with drug duration and therapy sequencing.
For the future, Dr van Akkooi and his group aim to initiate active trials for a range of melanoma patients, including those with advanced metastatic disease, brain metastases, ocular and UV melanoma.